Peer-influenced content. Sources you trust. No registration required. This is HCN.
OBR Oncology
Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.
Hematology/Oncology April 8th 2024
MDLinx
Amtagvi’s approval introduces a novel approach in the treatment of advanced melanoma, employing patient-derived TIL-cell therapy to target tumors with precision, offering a beacon of hope for those with limited options.
Dermatology March 4th 2024
Medical Professionals Reference (MPR)
Explore groundbreaking therapies in the pipeline: Onivyde for pancreatic cancer, showing marked survival benefits, and roluperidone, offering new hope in managing schizophrenia’s negative symptoms.
Hematology/Oncology January 22nd 2024
The New England Journal of Medicine
A look into the complexities of managing advanced melanoma with BRAF–MEK inhibitors, highlighting a case study where treatment-induced toxic effects posed significant diagnostic and therapeutic challenges.
Cancer Therapy Advisor
Discover how pre-surgery treatment with T-VEC can significantly improve long-term survival rates in advanced melanoma patients, as revealed in a recent phase 2 trial.
Dermatology October 2nd 2023
Clinical Advances in Hematology & Oncology
Explore the intricacies of diagnosing and treating acral melanoma, a subtype that presents unique challenges but also offers new avenues for targeted therapies and immune modulation.
Oncology, Medical August 28th 2023